Výsledky vyhledávání

Akademický článek

Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch

Autor: José-Manuel Carrascosa, Alessandra Narcisi, Toshifumi Nomura, Sonja Ständer, Christian Vestergaard, Silvia Sabatino, Susanne Grond, Uffe Koppelhus, Mohamed Elrayes, Yun-Fei Chen, Chunyuan Liu, Andreas Wollenberg

Publikováno v: Dermatology and Therapy, Vol 14, Iss 6, Pp 1561-1573 (2024)

Abstract Introduction Patients with moderate-to-severe atopic dermatitis (AD) who are most likely to respond to the Janus kinase (JAK) 1/2 inhibitor baricitinib (BARI) are known to have an impacted body surface area (BSA) ≤ 40% and severe itch (num

Externí odkaz: https://doaj.org/article/81d36fcca80b41c59d44c9c0c4c98e6f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Publikováno v: Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)

Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet

Externí odkaz: https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Autor: Paolo Amerio, Silvia Mariel Ferrucci, Marco Galluzzo, Maddalena Napolitano, Alessandra Narcisi, Anna Levi, Sara Di Fino, Chiara Palladino, Cataldo Patruno, Mariateresa Rossi

Publikováno v: Dermatology and Therapy, Vol 14, Iss 6, Pp 1443-1455 (2024)

Abstract Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading

Externí odkaz: https://doaj.org/article/dca1283cbe5b447288e6cb7dd29a8cc6

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

On the Scalability of a Membrane Unit for Ultrapure Hydrogen Separation

Autor: Vincenzo Narcisi, Luca Farina, Alessia Santucci

Publikováno v: Hydrogen, Vol 5, Iss 2, Pp 149-162 (2024)

Hydrogen permeation sparked a renewed interest in the second half of the 20th century due to the favorable features of this element as an energy factor. Furthermore, niche applications such as nuclear fusion gained attention for the highest selectivi

Externí odkaz: https://doaj.org/article/9559a83007bf49c49279a516ff3bf752

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Autor: Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi

Publikováno v: Dermatology and Therapy, Vol 14, Iss 4, Pp 919-932 (2024)

Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of p

Externí odkaz: https://doaj.org/article/7023be759f84421298febcd280592b42

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

Autor: Ibba L, Gargiulo L, Vignoli CA, Fiorillo G, Valenti M, Costanzo A, Narcisi A

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 593-604 (2024)

Luciano Ibba,1,2 Luigi Gargiulo,1,2 Carlo Alberto Vignoli,1,2 Giovanni Fiorillo,1,2 Mario Valenti,1,2 Antonio Costanzo,1,2 Alessandra Narcisi1 1Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy; 2Department of Biomedical Sciences, Hum

Externí odkaz: https://doaj.org/article/3579111330274e7f89ce3c1e198e513e

Zobrazit plný text záznamu

Akademický článek

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study

Autor: Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Background: Psoriasis is a chronic skin disease driven by immune system dysfunction and associated with increased cardiovascular risk and metabolic disorders. Risankizumab is an anti-interleukin-23 humanized monoclonal antibody approved for the treat

Externí odkaz: https://doaj.org/article/410ba8e4d65144ce8b9d47ad0f64e2ad

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání